LSE - Delayed Quote GBp

Avacta Group Plc (AVCT.L)

33.60
-1.40
(-4.00%)
At close: June 13 at 5:10:34 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for AVCT.L

Recent News: AVCT.L

View More
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors

Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
GlobeNewswire 17 days ago
Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting

Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting
GlobeNewswire last month
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting

Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting
GlobeNewswire last month
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives

Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
GlobeNewswire 2 months ago
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
GlobeNewswire 2 months ago
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
GlobeNewswire 3 months ago
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
GlobeNewswire 3 months ago
Avacta Therapeutics reports data from trial of AVA6000 for salivary gland cancer

Avacta Therapeutics reports data from trial of AVA6000 for salivary gland cancer
Clinical Trials Arena 4 months ago
While institutions own 41% of Avacta Group Plc (LON:AVCT), individual investors are its largest shareholders with 57% ownership

While institutions own 41% of Avacta Group Plc (LON:AVCT), individual investors are its largest shareholders with 57% ownership
Simply Wall St. 5 months ago
Investors in Avacta Group (LON:AVCT) have seen splendid returns of 163% over the past five years

Investors in Avacta Group (LON:AVCT) have seen splendid returns of 163% over the past five years
Simply Wall St. 6 months ago
Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona
GlobeNewswire 7 months ago
View More

Related Tickers

HVO.L hVIVO plc
11.00
-4.35%
 
SCLP.L Scancell Holdings plc
9.88
0.00%
 
APE.F Addex Therapeutics SA N
0.0595
+1.71%
 
OXB.L Oxford Biomedica plc
324.00
-2.41%
 
SYGGF Synairgen plc
0.0001
0.00%
 
HEMO.L Hemogenyx Pharmaceuticals Plc
177.50
+0.14%
 
FARN.L Faron Pharmaceuticals Oy
230.00
+1.10%
 
FUM.L Futura Medical plc
9.10
+1.11%
 
DBV.PA DBV Technologies S.A.
1.5860
-3.65%
 
PRTG Portage Biotech Inc.
5.99
-5.07%